ASH 2014: Phase II/III study of lenalidomide in relapsed/refractory diffuse large B-cell lymphoma - European Medical Journal

Continue

ASH 2014: Phase II/III study of lenalidomide in relapsed/refractory diffuse large B-cell lymphoma

Oncology

Dr Andrew Davies (University of Southampton, Southampton, UK) at the 2014 American Society of Hematology (ASH) Annual Meeting discusses a phase II/III study comparing the efficacy and safety of lenalidomide versus investigator’s choice in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Studies continue to support the clinical importance of molecularly distinct subtypes of DLBCL.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.

Thank you!

Please share some more information on the rating you have given